# US 2025/0027041 A1 · Composition for inducing transdifferentiation and stem cells treated therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027041 A1
- Document ID: US20250027041A1
- Status: Published application
- Kind: A1
- Application number: 18/712,101
- Filed: 2022-11-21
- Published: 2025-01-23
- Earliest claimed: 2021-11-22
- Assignees: Yj Cerapeutics Inc.
- Applicants: Yj Cerapeutics Inc.
- Inventors: Tae Young YUNE; Jee Youn LEE
- Web page: https://patentgrep.com/patent/US20250027041A1

## CPC

- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 5/0623: {Stem cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- C12N 5/0619: {Neurons}
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a composition for inducing direct conversion through oligomerization of CtBPs, and uses of stem cells treated therewith. Since the compounds of the present invention can induce transdifferentiation of adult stem cells into neural progenitor cells by regulating the oligomerization of CtBPs, the compounds can be used for inducing oligomerization of CtBPs or direct conversion. In addition, since ciNSC5 derived from direct conversion exhibits remarkable therapeutic effects in an ALS mouse model, an MS mouse model, a PD rat model, and a chronic spinal cord injury rat model, ciNSC5 can be used as a cellular therapeutic agent.

## Claims

### Claim 1

A method for inducing oligomerization of C-terminal Binding Proteins (CtBPs), comprising treating a sample in vitro with at least one selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3:

### Claim 2 (depends on 1)

The method for inducing oligomerization of CtBPs of claim 1, wherein the sample is an adult stem cell.

### Claim at position 3

3-11. (canceled)

### Claim 12 (depends on 1)

The method for inducing oligomerization of CtBPs of claim 1, wherein an expression of Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein or TBR2 protein is increased in the sample after treatment compared to before treatment with the compound.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method for inducing oligomerization of CtBPs of claim 1, wherein a secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 is increased in the sample after treatment compared to before treatment with the compound.

### Claim at position 7

15-18. (canceled)

### Claim 19 (depends on 1)

The method for inducing oligomerization of CtBPs of claim 1, wherein an expression of CD44, CD73 or CD105 is decreased in the sample after treatment compared to before treatment with the compound.

### Claim 20

A method for inducing direct conversion of adult stem cells into neural progenitor cells, comprising treating adult stem cells with at least one selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3 in vitro,
wherein the oligomerization of CtBPs induced in neural progenitor cells.

### Claim 21 (depends on 20)

The method for inducing direct conversion of claim 20, wherein an expression of Tuj1, CD325 (N-cadherin), p75, GAP-43, CD54, CD309, CD56 (NCAM), PSA-NCAM, CD29, MASH1 or TBR2 is increased in the cells after treatment compared to before treatment with the compound.

### Claim 22 (depends on 20)

The method for inducing direct conversion of claim 20, wherein a secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 is increased in the cells after treatment compared to before treatment with the compound.

### Claim 23 (depends on 20)

The method for inducing direct conversion of claim 20, wherein an expression of CD44, CD73 or CD105 is decreased in the cells after treatment compared to before treatment with the compound.

### Claim 24

Stem cells treated with at least one compound selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3 below:
wherein the oligomerization of CtBPs induced in neural progenitor cells.

### Claim 25 (depends on 24)

The stem cells of claim 24, wherein the stem cells treated with the compound are adult stem cells.

### Claim 26 (depends on 25)

The stem cells of claim 25, wherein the adult stem cells are umbilical cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (UC-MSC), adipose-derived mesenchymal stem cells (AD-MSC) or bone marrow-derived mesenchymal stem cells (BM-MSC).

### Claim 27 (depends on 24)

The stem cells of claim 24, wherein at least one selected from the group consisting of the compound of Chemical Formula 1, the compound of Chemical Formula 2, and the compound of Chemical Formula 3 is treated in vitro for 3 to 7 days.

### Claim 28 (depends on 24)

The stem cells of claim 24, wherein the adult stem cells are direct converted into neural progenitor cells by treatment with the compound.

### Claim 29

(canceled)

### Claim 30 (depends on 24)

The stem cells of claim 24, wherein an expression of Tuj1, TBR2, MASH1, GAP-43 or p75 is increased compared to stem cells untreated with the compound.

### Claim 31 (depends on 24)

The stem cells of claim 24, wherein an expression of Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD54 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein or TBR2 protein is increased compared to stem cells untreated with the compound.

### Claim 32 (depends on 24)

The stem cells of claim 24, wherein an expression of CD44, CD73 or CD105 is decreased compared to stem cells untreated with the compound.

### Claim 33 (depends on 24)

The stem cells of claim 24, wherein a secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 is increased compared to stem cells untreated with the compound.

### Claim 34 (depends on 24)

The stem cells of claim 24, wherein the expression of HES1, Sox2 or OCT4 is increased compared to stem cells untreated with the compound.

### Claim 35

(canceled)

### Claim 36 (depends on 24)

The stem cells of claim 24, wherein MAP2, NSE, NeuN, doublecortin, Neurogenic differentiation 1 (NeuroD1), Nestin, Mussashi 1 or GFAP is not expressed.

### Claim at position 26

37-45. (canceled)
